Variations in genes such as patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), membrane bound O-acyltransferase domain-containing 7 gene (MBOAT7), glucokinase regulator (GCKR), hydroxysteroid 17-beta dehydrogenase-13 (HSD17B13) have been identified as key modifiers of NAFLD development and progression (8). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.